Skip to main content

Table 2 Univariate analysis of predictions of overall survival of men with metastatic castration-resistant prostate cancer treated with cabazitaxel

From: Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel

  HR 95% CI P value
Lower Upper
Age (≥71.2 years vs < 71.2) 2.6 1.1 6.0 0.023
Number of cycles of docetaxel (≥10 cycles vs ≤9) 0.8 0.4 1.7 0.533
Baseline aBSI (≥1.0% vs < 1.0) 3.1 1.1 9.2 0.036
Baseline PSA (≥152.1 ng/mL vs < 152.1) 1.7 0.7 3.7 0.218
Baseline Hb (<  11.0 g/dL vs ≥11.0) 3.6 1.6 8.1 0.002
Baseline LDH (≥262 IU/L vs < 262) 3.0 1.3 6.5 0.008
Baseline ALP (≥414 IU/L vs < 414) 2.0 0.9 4.5 0.100
  1. aBSI automated bone scan index, ALP alkaline phosphatase, Hb hemoglobin, LDH lactate dehydrogenase, PSA prostate-specific antigen